Alterity Therapeutics Limited (ATHE)
Nasdaq: ATHE · Pharmaceutical Preparations · Melbourne, AU · filing with the SEC since 2002
Who runs Alterity Therapeutics Limited
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Stamler David Allen
Chief Executive Officer. First filing Apr 2026, latest Sep 8, 2026, 0 filings in all.
Officers reporting now
2
of 6 people with a filing in the last fifteen months
Directors reporting now
4
6 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Stamler David Allen | Chief Executive Officer | Apr 2026 | Sep 8, 2026 | none |
| Macnish Niven Abby Sarah | Chief Financial Officer | Apr 2026 | Apr 9, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Marks Peter Ashley | director | Apr 2026 | Sep 8, 2026 | none |
| Babarczy Julian Michael | director | Apr 2026 | Jun 23, 2026 | none |
| Gozlan Lawrence Bernard | director | Apr 2026 | Jun 23, 2026 | none |
| Cunningham Ann Michelle | director | Apr 2026 | Apr 29, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.